Macroaxis: Personalized Investing
Simple Personalized Investing

S&P 500   1,667   17.00  Index Moved Up 1.03%
JNJ PFE NVS SNY Entertainment Compulsion Management Macroaxis Picks 
United States  USA  |  Create Portfolios


Processing
Processing. Please wait...

Pfizer Debt to Equity

 
 Companies |  Insiders  | Dashboard  
     

Debt to Equity breakdown for Pfizer

Debt to Equity is calculated by dividing the Total Debt of a company by its Equity. If the debt exceeds equity of a company then the creditors have more stakes in a firm than the stockholders. In other words, Debt to Equity ratio provides analysts with insights about composition of both equity and debt, and its influence on the valuation of the company.

Pfizer

D/E

=

Total Debt

Total Equity

=
0.49 times
High Debt to Equity ratio typically indicates that a firm has been barrowing aggressive to finance its growth and as a result may experience a burden of additional interest expense. This may reduce earnings or future growth. On the other hand small D/E ratio may indicate that a company is not taking enough advantage from financial leverage. Debt to Equity ratio measures how the company is leveraging barrowing against the capital invested by the owners.
Compare Pfizer to competition

Pfizer Debt to Equity Assessment

According to company disclosure Pfizer Inc has Debt to Equity of 0.49 times. This is 16.95% lower than that of Healthcare sector, and 22.22% lower than that of Drug Manufacturers - Major industry, The Debt to Equity for all stocks is 19.51% lower than the firm.

Filter other Stocks by Debt to Equity

Select Debt to Equity Range
Current Range 
Indicate Industry
Click to run this filter
 Run Equity Filter
Filter Other Equities
  

Debt to Equity Comparison

Pfizer is regarded third in debt to equity category among related companies.
Follow Pfizer Debt to Equity with Macroaxis syndicated feed, custom widget, or your favorite custom stock ticker
Add To Reader
 
Add Pfizer to your reader
 
    
PFE United States NYSE
Pfizer Inc
Currency: USD - US Dollar
Traded on New York Stock Exchange
    
    

Other Pfizer Fundamentals

Return On Equity12.68 %
Return On Asset6.78 %
Profit Margin26.95 %
Operating Margin35.10 %
Current Valuation208.83 B
Shares Outstanding7.09 B
Shares Owned by Insiders0.02 %
Shares Owned by Institutions72.60 %
Number of Shares Shorted63.42 M
Price to Earning13.86 times
Price to Book2.52 times
Price to Sales3.60 times
Revenue57.6 B
Gross Profit47.65 B
EBITDA26.8 B
Net Income10.52 B
Cash and Equivalents35.35 B
Cash per Share4.98 times
Total Debt40.38 B
Debt to Equity0.49 times
Current Ratio2.35 times
Book Value Per Share11.59 times
Cash Flow from Operations16.52 B
Short Ratio1.80 times
One Year High31.15
One Year Low21.4
Earnings Per Share2.09 times
Price to Earnings To Growth4.73 times
Number of Employees91.5 K
Beta0.81
Market Capitalization205.42 B
Total Asset187.4 B
Retained Earnings56.97 B
Working Capital37.22 B
Current Asset64.76 B
Current Liabilities27.54 B
Z Score3.0
Probability Of Bankruptcy29.00 %


 
Analytics
Risk Adjusted Returns Landscape
Live Efficient Frontier
Market Correlation Analysis
Watchlist Analysis
Financial Content
Portfolio Estimation and Projections
Portfolio Theme Builder
 
 
Research Modules
Equities Backtesting Analysis
Instant Retirement Optimizer
Cross-portfolio RSS and Mobile Access
Company, fund, and ETF Directory
Financial Advisor Directory
Insider and Manager Directory
Wealth Management
 Gadgets, Widgets, and Apps          
  
 
Services And Technology
Frequently Asked Questions
Quick Product Tour
Product Technology Overview
Solution Methodology
Plans and Pricing
 
Free Investor Tools
World Market Correlations
Instant Equity Comparator
Watchlist Analysis
Position Suggestions
Equity Alpha Analysis
 
About Us
About Macroaxis
Contact Us
Product Terms Of Use
Service Privacy Policy
Advertising Opportunities
Content

Thanks for checking out Macroaxis

Tell us what you like and what you don't like. We promise we'll not only listen but write you back

Contact Us
Macroaxis is user-driven community of investors. We appreciate any feedback or comment you can provide. Please fill out our quick survey to help us provide your with a better service and user experience

Fill Out Quick Survey
Most of the functionality on our site is free to use. However we do provide premium service to sophisticated investors. Our premium subscription will give you unprecedented capabilities to optimize your portfolios using robust financial analysis toolkit, fast mean-variance optimization engine, and proven portfolio theory

Go Premium